Four Options in Colorectal CancerAnother practice-changing study—CALGB/SWOG 80405— sought to determine whether there is an optimal first-line treatment for patients with untreated metastatic colorectal cancer without KRAS mutations by comparing chemotherapy plus either bevacizumab or cetuximab.
CHICAGO—The consequences of diminishing federal support for cancer research can be measured in the abstracts presented at the 50th annual meeting of the American Society of Clinical Oncology that concluded earlier this week.
FDA approved the Amgen agent Vectibix (panitumumab) for use in combination with FOLFOX as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer.
The Special Awards honorees at the 2014 meeting of the American Society of Clinical Oncology are:
Moffitt Cancer Center and the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute earlier this week announced that they are constructing a bioinformatics framework that would enable a multi-center collaboration.
Douglas Boyd, a professor at MD Anderson, sent his own letter to the American Association of University Professors, responding to DePinho's version of events.
Responding to an inquiry by the American Association of University Professors, MD Anderson Cancer Center President Ronald DePinho said his critics are incorrect in asserting that his administration gave no formal explanation for denying tenure renewal to two faculty members.
Confronted with the prospect of censure by an academic freedom group, Ronald DePinho, president of MD Anderson Cancer Center, is defending his decision to deny tenure renewal to two faculty members.
Selma Ruth Schimmel died on May 21 from malignant psoas syndrome, a complication of the ovarian cancer, for which she was being treated. Schimmel, 59, died at Providence Tarzana Medical Center near her home in Los Angeles.
As funding issues surrounding the NCI's new National Clinical Trials Network (NCTN) have been a prominent topic of recent news and discussions, to help inform the cancer research community, we are taking this opportunity to share data regarding NCTN funding to the Children's Oncology Group (COG).
